E-LIB Suche - Ergebnisse für: Fox, Norma Lynn

1

Disruption of memory B-cell trafficking by belimumab in pat..:

Arends, Eline J ; Zlei, Mihaela ; Tipton, Christopher M...
Rheumatology. , 2024

Link: https://doi.org/10.1093/..

2

Impact of Belimumab on Organ Damage in Systemic Lupus Eryth..:

Urowitz, Murray B. ; Aranow, Cynthia ; Asukai, Yumi...
Arthritis Care & Research. 74 (2022) 11 - p. 1822-1828 , 2022

Link: https://doi.org/10.1002/..

3

10 Years of belimumab experience: What have we learnt?:

Levy, Roger A ; Gonzalez-Rivera, Tania ; Khamashta, Munther...
Lupus. 30 (2021) 11 - p. 1705-1721 , 2021

Link: https://doi.org/10.1177/..

4

Treating Opioid Use Disorder With a Monthly Subcutaneous Bu..:

Andorn, Anne C. ; Haight, Barbara R. ; Shinde, Sunita...
Journal of Clinical Psychopharmacology. 40 (2020) 3 - p. 231-239 , 2020

Link: https://doi.org/10.1097/..

5

Clinical response beyond the Systemic Lupus Erythematosus R..:

van Vollenhoven, Ronald F ; Stohl, William ; Furie, Richard A...
Lupus Science & Medicine. 5 (2018) 1 - p. e000288 , 2018

Link: https://doi.org/10.1136/..

6

Efficacy and Safety of Subcutaneous Belimumab in Systemic L..:

Stohl, William ; Schwarting, Andreas ; Okada, Masato...
Arthritis & Rheumatology. 69 (2017) 5 - p. 1016-1027 , 2017

Link: https://doi.org/10.1002/..

7

Evaluation of a novel autoinjector for subcutaneous self-ad..:

Sheikh, Saira Z. ; Hammer, Anne E. ; Fox, Norma Lynn...
Int. Journal of Clinical Pharmacology and Therapeutics. 54 (2016) 11 - p. 914-922 , 2016

Link: https://doi.org/10.5414/..

8

Relative Bioavailability of a Single Dose of Belimumab Admi..:

Struemper, Herbert ; Murtaugh, Thomas ; Gilbert, Jane...
Clinical Pharmacology in Drug Development. 5 (2015) 3 - p. 208-215 , 2015

Link: https://doi.org/10.1002/..

9

Phase II Trial of Mapatumumab, a Fully Human Agonist Monocl..:

von Pawel, Joachim ; Harvey, Jimmie H. ; Spigel, David R....
Clinical Lung Cancer. 15 (2014) 3 - p. 188-196.e2 , 2014

Link: https://doi.org/10.1016/..

10

Laying strong foundations:

Fox, Norma Lynn
Reproductive BioMedicine Online. 23 (2011) - p. 26-27 , 2011

Link: https://doi.org/10.1016/..

11

Determination of a weight-adjusted dose of TNK–tissue plasm..:

Wang-Clow, Fong ; Fox, Norma Lynn ; Cannon, Christopher P....
American Heart Journal. 141 (2001) 1 - p. 33-40 , 2001

Link: https://doi.org/10.1067/..

12

Pharmacokinetics and Pharmacodynamics of Tenecteplase: Resu..:

Modi, Nishit B. ; Fox, Norma Lynn ; Clow, Fong‐Wong...
The Journal of Clinical Pharmacology. 40 (2000) 5 - p. 508-515 , 2000

Link: https://doi.org/10.1177/..

13

Weight-adjusted dosing of TNK-tissue plasminogen activator ..:

Gibson, C.Michael ; Cannon, Christopher P ; Murphy, Sabina A...
The American Journal of Cardiology. 84 (1999) 9 - p. 976-980 , 1999

Link: https://doi.org/10.1016/..

14

Safety assessment of single-bolus administration of TNK tis..:

Van de Werf, Frans ; Cannon, Christopher P. ; Luyten, Anne...
American Heart Journal. 137 (1999) 5 - p. 786-791 , 1999

Link: https://doi.org/10.1016/..

15

TNK-Tissue Plasminogen Activator in Acute Myocardial Infarc..:

Cannon, Christopher P. ; McCabe, Carolyn H. ; Gibson, C. Michael...
Circulation. 95 (1997) 2 - p. 351-356 , 1997

Link: https://doi.org/10.1161/..